Abstract Purpose: Gemcitabine is a promising adjuvant treatment for patients with resected pancreatic adenocarcinoma and its use in combination with radiotherapy is under exploration. Human equilibrative nucleoside transporter 1(hENT1) and human concentrative nucleoside transporter (hCNT) 1and 3 are the major transporters responsible for 2 ¶,2 ¶-difluoro-2-deoxycytidine (gemcitabine) uptake into cells. The aim of this study was to determine patients' outcome according to the expression of hENT1 and hCNT3 in tumoral cells after postoperative gemcitabine-based chemoradiation regimen. Experimental Design: We studied tumor blocks from 45 pancreatic adenocarcinoma patients treated with gemcitabine-based chemoradiation after curative resection and assessed hENT1and hCNT3 expression using immunohistochemistry. Results: When adjusted for the effects of lymph node ratio and tumor diameter, patients with high hENT1 expression had significantly longer disease-free survival and overall survival (OS) than patients with low expression, whereas high hCNT3 expression was only associated with longer OS. In a combined analysis, patients with two favorable prognostic factors (hENT1 high / hCNT3 high expression) had a longer survival (median OS, 94.8 months) than those having one (median OS, 18.7 months) or no (median OS, 12.2 months) favorable prognostic factor. Conclusions: Pancreatic adenocarcinoma patients with a high expression of hENT1and hCNT3 immunostaining have a significantly longer survival after adjuvant gemcitabine-based chemoradiation. These biomarkers deserve prospective evaluation in patients receiving gemcitabinebased adjuvant therapy.
Pancreatic head adenocarcinoma has a very poor prognosis.
Even after curative surgery, which concerns only 10% to 15% of patients at the time of the diagnosis, 5-year survival is only 10% to 20% and median survival is 20 to 24 months (1, 2) . This poor survival rate is attributed to a high rate of local recurrence and development of distant metastases even after complete resection of the tumor (R0 surgery). Several multimodal adjuvant and neoadjuvant therapies have been developed to reduce both local and systemic recurrence of the disease and improve survival. Nevertheless, the value of such adjuvant radiotherapy and/or chemotherapy regimens remains questionable because several trials have failed to draw any firm conclusions. Most of these adjuvant treatments were based on the combination of radiation and 5-fluorouracil (2 -5) .
Gemcitabine is a 2 ¶,2 ¶-difluoro-2-deoxycytidine analogue that inhibits DNA replication and repair. Gemcitabine monotherapy has clinically important activity in advanced and metastatic pancreatic adenocarcinoma and for which it is now the standard of care (6) . In the adjuvant setting, it was enhanced disease-free survival (DFS) and survival compared with surgery alone (7, 8) and significantly increased DFS, but not overall survival (OS), when added to 5-fluorouracil-based chemoradiotherapy in a recent RTOG trial (9) .
As gemcitabine possesses radiosensitizing properties in both in vitro and in vivo models (10 -13) , there is a rationale to combine it with radiotherapy in the neoadjuvant and adjuvant setting. Emerging data, including ours (11 -17) , have shown a good tolerability and feasibility and this combined regimen is now further being explored in a randomized phase III trial.
Gemcitabine is a prodrug that is phosphorylated by deoxycytidine kinase to its mononucleotide in the rate-limiting step of its cellular anabolism. Subsequent nucleotide kinases convert gemcitabine monophosphate to its active metabolites, gemcitabine diphosphate and gemcitabine triphosphate (18, 19) . The de novo DNA synthesis pathway is blocked through inhibition of ribonucleotide reductase by gemcitabine diphosphate (20) . Permeation of gemcitabine through the plasma membrane requires specialized integral membrane nucleoside transporters proteins. Among these transporters, the major mediators of gemcitabine uptake into human cells appear to be the human equilibrative nucleoside transporter 1 (hENT1) and, to a lesser degree, the human concentrative nucleoside transporter 3 (hCNT3; refs. [21] [22] [23] [24] . Cells lacking hENT1 are highly resistant to gemcitabine (23, 25) and metastatic pancreatic cancer patients with hENT1 expression had significantly longer survival after gemcitabine chemotherapy than patients affected by tumors without detectable hENT1 (26) .
Based on the apparent importance of nucleoside transporters to gemcitabine activity in pancreatic cancer, we explored the prognostic value of the tumoral expression of the nucleoside transporter proteins hENT1 and hCNT3 in a cohort of subjects with resected pancreatic adenocarcinoma, who received adjuvant gemcitabine-based chemoradiotherapy.
Patients and Methods
Patient populations. Patients from two Belgian multicentric phase II studies evaluating the feasibility of adjuvant gemcitabine-based combined regimen in resected pancreatic cancer patients between 2000 and 2003 were studied (15, 16) . Both studies were approved by the ethics committees of each participating center. Standardized surgical procedures of pylorus-preserving duodenopancreatectomy or standard Whipple duodenopancreatectomy were done by one of two experienced surgeons in each center. During surgery, metallic or titanium clips were placed to delineate the original tumor limits for further determination of the target volume of irradiation. The eligibility criteria were similar for both studies: previous R0 resection with complete recovery from surgery within 8 weeks; stage I, II, or III (zT 2 N 0 ) histologically proven adenocarcinoma of the pancreatic head; age z18 years; Eastern Cooperative Oncology Group performance status (PS) V2; absence of previous or coexistent malignancy, adequate bone marrow, liver, and renal function; no previous chemotherapy or radiotherapy; and expected survival z6 months. Patients with cystic or neuroendocrine tumors were excluded. Proper documentation related to the number of the lymph nodes examined was mandatory. Abdominal computed tomography was done just before starting combined therapy to exclude the possible presence of early progressive disease. Patients were followed every 3 months by serial computed tomography and or magnetic resonance imaging and CA19.9 measurements until death to determine recurrence. Recurrence was proven by imaging.
Adjuvant treatment plan. Treatment was planned to start within 8 weeks post-surgery. Each patient was assigned to receive two cycles of gemcitabine 1,000 mg/m 2 weekly as a 30 min infusion for 3 of 4 weeks. After 1 week rest, chemoradiation was started. Gemcitabine 300 mg/m 2 as a 30 min infusion was given weekly for 5 consecutive weeks and administered 4 h before application of radiation (12) . Patients received 40 Gy (n = 15) to 50.4 Gy (n = 30) according to the two trials (12, 13) .
Immunohistochemistry. Anti-hENT1 and anti-hCNT3 monoclonal antibodies were produced and characterized as described previously (27, 28) . Goat anti-mouse antibodies and horseradish peroxidaselabeled dextran polymer (DAKO EnVision+) were purchased from DAKO. All other reagents were of analytic grade and commercially available. Each formalin-fixed, paraffin-embedded pancreatic section (4-6 Am thick) was deparaffinized with three immersions in xylene baths (10 min each) followed by serial washes in graded alcohol from 100% to 50%. After rinsing in water, slides were placed in 250 mL high pH 1Â DAKO target antigen retrieval solution and microwaved in TTmega Milestone (ESBE Scientific) under control temperature and high pressure for 10 min at 100jC. After cooling in water for 6 min, slides were rinsed with water and peroxidase blocked in 3% H 2 O 2 solution with methanol for 10 min and then washed in running water for 10 min. PBS (pH 7.2) was used for rinsing before incubation with appropriate dilutions of anti-hENT1 monoclonal antibodies. Slides with anti-hENT1 were incubated in a humidified chamber overnight at 4jC. Slides with anti-hCNT3 were incubated at room temperature for 30 min. The sections were then rinsed with PBS, immersed in buffer for 5 min, and incubated with goat anti-mouse dextran conjugate (DAKO Envision+) for 30 min followed by soaking in PBS. DAKO diaminobenzidine liquid chromagen was placed on the samples for 5 min and rinsed, after which the slides were soaked in 1% CuSO 4 for another 5 min. Subsequently, the sections were rinsed, counterstained with hematoxylin, dehydrated through graded alcohol and xylene, and finally coverslipped. Negative controls were provided by omitting the primary antibodies and by using antibody preparations from which anti-hCNT3 and anti-hENT1 antibodies had been removed by incubation with an excess of the appropriate peptide.
Immunohistochemical evaluation. Quantitative scoring using light microscopy was done by a single pathologist (R.L.) blinded to clinical characteristics and outcomes. Immunohistochemical scoring was done only on invasive adenocarcinoma cells of one representative stained slide each for hENT1 and hCNT3.
Staining of hENT1 and hCNT3 protein was assigned a score from 0 to 3 based on staining intensity with 0 = no staining, 1 = weakly positive, 2 = moderately positive, and 3 = strongly positive. The percentage of adenocarcinoma cells staining at each intensity level was recorded for each specimen. A final score was determined by multiplying the intensity score and the percentage of the specimen. For example, if a specimen exhibited a staining distribution of 30% 1+ and 60% 2+, the final score is 150 (1 Â 30 + 2 Â 60). Therefore, the weighted scores ranged between 0 and 300.
Statistical methods. DFS was defined as the time from the date of surgery to the date of first relapse or death. OS was calculated from the date of surgery to the date of death. Data on survivors were censored at
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the last follow-up. The Kaplan-Meier method was used to plot DFS and OS (29) and differences based on biomarker status were evaluated with the log-rank test (30) . A Cox proportional hazards univariate and multivariate model (31) were used to corroborate the association of clinical and pathologic factors and the tumoral expression of hENT1 and hCNT3 proteins with DFS and OS. Multivariate analyses used a backward stepwise procedure based on the likelihood ratio test. Data were analyzed using SPSS version 10.0 (SPSS). Statistical significance was set at P < 0.05.
Results
Patient population, adjuvant therapy, and clinical outcome. A total of 45 patients were studied. They were 23 men and 22 women, median PS 0 (range, 0-1), and median age 58 years (range, 34-83). There were 34 patients with tumor-nodemetastasis stage III and 18 patients with stage II. The median delay between surgery and the beginning of adjuvant therapy was 45 days (range, 24-74). Patients' pretreatment characteristics are described in Table 1 . Adjuvant chemoradiation regimens were well tolerated and completed in 43 of 45 (95%) of the patients. WHO grade III/IV hematologic toxicities was noticed in 10 of 45 (21%) patients and nonhematologic grade III/IV in 3 of 45 (7%) patients. Only 2 patients required complication-related hospitalization after adjuvant treatment. Median follow-up was 21.9 months (range, 3.3-107.4) after surgery. Overall, median DFS and OS were 13.0 months (range, 1-107.4) and 21.9 months (range, 3.3-107.4), respectively. At the time of the last follow-up, 30 patients had died due to disease recurrence (distant n = 17, local n = 8, and local + distant n = 5). Fifteen patients were still alive at the last visit (range, 24.9-107.4 months).
Immunostaining of hENT1 and hCNT3. The immunohistochemical hENT1 staining was present within the islets of Langerhans cells and lymphocytes, as reported previously, and used as internal positive controls. Within carcinoma cells, hENT1 protein and hCNT3 staining were localized to the cytoplasm (Fig. 1) . In 45 tumor samples, 7 (16%) samples had uniformly detectable hENT1 immunostaining (intensity scores of 1+ and/or 2+ and/or 3+) with no regions lacking hENT1, and the remaining 38 samples possessed a proportion (range, 11-100%) of adenocarcinoma cells without detectable hENT1 (intensity score of 0). In contrast, each of these 45 tumors had detectable hCNT3 immunostaining of at least 1+ intensity. hCNT3 staining intensity was heterogeneous, both within some tumors, and in comparison between individual tumors. We dichotomized hENT1 staining based on the median value of the staining score. By this criterion, the cutpoint was 80, and patients were divided in two groups: (a) low hENT1 expression (staining score <80) and (b) high hENT1 expression (staining score z80; Fig. 1 ). For hCNT3, the cutoff value was 150. Accordingly, we define two groups: (a) low hCNT3 expression (staining score <150) and (b) high hCNT3 expression(staining score z150; Fig. 1) .
Correlation between hENT1 and hCNT3 expression and patients' outcome. The survival curves according to tumoral hENT1 and hCNT3 expression are shown in Fig. 2 . Both OS and DFS correlated with hENT1 expression. The median OS was 13.3 months [95% confidence interval (95% CI), 8.5-16.7] and 3-year survival was 19.2% (95% CI, 11.5-26.9) for patients with low hENT1 expression, whereas the median OS was not yet reached during the follow-up period for the patients with high hENT1 expression [hazard ratio (HR) for death, 4.31; 95% CI, 1.95-9.52; P = 0.0001] and 3-year survival was 68.4% (95% CI, 57.7-79.1; P = 0.0007). The median DFS was 8.4 months (95% CI, 4.6-12.1) for patients with low expression and 46.8 months (95% CI, 30.3-93.9) for patients with high expression (HR for disease recurrence, 4.36; 95% CI, 2.01-9.44; P = 0.0001).
In the same way, patients with low hCNT3 expression showed a higher risk of disease recurrence (median DFS, 8.6 months; 95% CI, 5.6-11.6) than patients with high hCNT3 expression (median DFS, 23.5 months; 95% CI, 12.4-76.3; HR for DFS, 2.27; 95% CI, 1.12-4.65; P = 0.02) and a significant difference was observed between groups for OS [median OS, not yet reached during the follow-up period versus 12.6 months (95% CI, 7.7-17.5), respectively] and 3-year survival [54.6% (95% CI, 43.9-65.1) versus 26.1% (95% CI, 15.0-35.2; P = 0.028)] according to hCNT3 expression (HR for death, 2.59; 95% CI, 1.24-5.43; P = 0.003). Among clinicopathologic factors, tumor size was the lone to be correlated with DFS and OS ( Table 2 ). In a multivariate Cox proportional model that adjusted for the effect of lymph node metastasis, tumor size, Eastern Cooperative Oncology Group PS, age, CA19-9 level and lymph node ratio, and low hENT1 and hCNT3 expression were independent risk factors for death, whereas hENT1 was the only independent predictor for disease recurrence (Table 3) .
When we combined status of both hENT1 and hCNT3, for patients with two favorable prognostic factors (n = 15, both high hENT1 and hCNT3 expression), median OS was not reached compared with a median OS of 18.7 months (95% CI, 6.5-30.9) for patients with one favorable prognostic factor (n = 19, high hENT1 or hCNT3 expression; P = 0.0016) and 12.2 months (95% CI, 8.3-16.1) for patients with no favorable prognostic factors (n = 11; P < 0.0001; Fig. 3 ). The 3-year survival was 81.1% (95% CI, 71.4-90.8), 24.9% (95% CI, 14.1-36.7), and 23.1% (95% CI, 11.5-34.7; P < 0.0001), respectively, for the three groups.
Discussion
Gemcitabine chemotherapy is the current standard of care for palliation of advanced pancreatic cancer (3). In adjuvant setting, however, no single approach has achieved widespread acceptance. The activity of gemcitabine in advanced pancreatic cancer, and its radiosensitizing properties, led us to evaluate gemcitabine in combination with chemoradiotherapy to improve patients' outcomes after pancreatic adenocarcinoma resection. Chemoradiotherapy remains common in North American centers based on data from the Gastrointestinal Tumor Study Group and the RTOG 9074 studies (9, 32), whereas, in Europe, chemotherapy is the standard based on the results of the European Study Group for Pancreatic Cancer Trial 1 (4, 5) and CONKO-001 study (7, 8) .
We previously conducted two phase II multicentric studies evaluating (15, 16) adjuvant chemoradiotherapy with gemcitabine for completely resected pancreatic adenocarcinoma. Both regimens shared similar designs, were highly feasible, and produced limited toxicity. We observed potential benefit for a subset of these patients, as 30% were long-term survivors, and the median OS was 21.9 months despite a high percentage of nodal metastases (71%) and T 3 or T 4 disease (73%). The strategy of using gemcitabine monotherapy before beginning concurrent gemcitabine and radiotherapy spared those patients with early progression or difficulty in tolerating treatment toxicities of concurrent chemoradiotherapy.
Identification of a subset of patients who derive benefit from adjuvant therapy would further improve the risk: benefit ratio of adjuvant pancreas cancer treatment. Because gemcitabine remains the backbone of systemic therapy for pancreatic cancer, we evaluated two molecular biomarkers of potential relevance to gemcitabine sensitivity. In the present study, we analyzed tumor samples from 45 participants in our adjuvant pancreatic cancer chemoradiation studies to assess the prognostic value of the gemcitabine transporter proteins, hENT1 and hCNT3. Using immunohistochemistry, we found that patients with low tumor hENT1 and hCNT3 had a shorter DFS and OS times when compared with patients with high hENT1 or hCNT3 expression. In our multivariate analysis, expression of hENT1 was the only significant independent marker of DFS, whereas hENT1 and hCNT3 were the only independent determinants of OS. hENT1 and hCNT3 status provided better prognostic information than tumor-node-metastasis classification, tumor diameter, lymph node status, ratio of positive nodes, and serum CA19.9 levels; furthermore, those patients with tumors exhibiting both high hENT1 and hCNT3 expression had particularly favorable outcome, with a mean survival exceeding 90 months. Although hENT1 and hCNT3 abundance within pancreatic tumor cells are prognostic markers for survival in our study, prospective molecular correlative studies should be done in trials where patients are randomized to either gemcitabine or a nonnucleoside therapy to prove whether hENT1 and hCNT3 are really predictive for benefit from adjuvant gemcitabine based-therapy and not simply a marker of prognosis.
These results are concordant with previous reports of the prognostic value of hENT1 in gemcitabine-treated pancreas cancer (26, 33, 34) . The absence of detectable hENT1 in metastatic pancreatic adenocarcinoma treated with gemcitabine was associated with a shorter OS compared with patients for whom hENT1 was present (26) . Giovannetti et al. showed in a retrospective cohort prolonged OS, DFS, and time to progression for patients with high levels of hENT1 mRNA (34) .
In aggregate, the consistency of the preclinical data (21 -25) with these clinical data strongly suggest that pancreatic adenocarcinoma cells are resistant to gemcitabine if they lack the transporter proteins required for efficient gemcitabine cellular entry. Although the majority of data support the central role of hENT1 in clinical gemcitabine sensitivity, the present study also suggests that hCNT3 may also meaningfully contribute to gemcitabine permeation in pancreatic adenocarcinoma. Furthermore, the observation that those patients with high expression of both hENT1 and hCNT3 had significantly better outcomes than those patients with high expression of only one transporter suggests that multiple transporters may incrementally increase cellular sensitivity; this has been reported in preclinical models, where introduction of hCNT1 by stable transfection increased the gemcitabine sensitivity of a pancreatic cell line producing high levels of hENT1 (24) . The emerging understanding of the cellular regulation of hENT1 and hCNT3 activities (35 -37) also raises the possibility of circumventing transporter-mediated drug resistance by upregulating nucleoside transporter activity.
Gemcitabine is a potent radiosensitizer of human pancreatic tumor cells (38) . Mechanisms of gemcitabine radiosensitization included dATP depletion (39, 40) , accumulation of cells in the S phase of the cell cycle (41) , and increased DNA residual damage. It is unknown whether nucleoside transporters are related to the ability of gemcitabine to radiosensitize pancreatic cancer cells. Furthermore, clarification for the relative contributions of gemcitabine induction chemotherapy and the chemoradiation therapy is needed and will deserve future comparison.
We conclude that the expression of hENT1 and hCNT3 provides independent prognostic information in pancreatic carcinoma patients treated with adjuvant gemcitabine-based chemoradiotherapy. Whether these assays provide sufficient predictive information to guide treatment decisions requires prospective evaluation in randomized clinical trials. However, the consistency and strength of the accumulating preclinical and translational data suggest that nucleoside transporters play an important role in clinical outcomes after gemcitabine adjuvant chemotherapy for pancreatic cancer.
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